Kyowa Kirin

Kyowa Kirin reported strong financial performance with TTM revenue of $3.16 billion as of December 2024, showing growth from $3.11 billion in 2023. The company, which operates as part of the Kirin Group, has been steadily increasing its international presence while maintaining a robust R&D investment ratio of 18-20% of revenue according to its FY2021-2025 Medium Term Business Plan. Their focus on biopharmaceuticals and specialized therapeutic areas has supported consistent revenue growth as they work toward achieving ROE of 10% or higher.